About the Authors
- Haley L. Yarosh
-
* E-mail: haley.yarosh@yale.edu
Affiliations Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Christopher J. Hyatt
-
Affiliation Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America
- Shashwath A. Meda
-
Affiliation Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America
- Rachel Jiantonio-Kelly
-
Affiliation Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America
- Marc N. Potenza
-
Affiliations Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America, Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America, Child Study Center, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Michal Assaf
-
Affiliations Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Godfrey D.Pearlson
-
Affiliations Olin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, Connecticut, United States of America, Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America, Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America
Competing Interests
Dr. Potenza has received financial support or compensation for the following: Dr. Potenza has consulted for and advised Somaxon, BoehringerIngelheim, Lundbeck and Ironwood Pharmaceuticals; has had financial interests in Somaxon; has received research support from the National Institutes of Health, Veteran’s Administration, Mohegan Sun Casino, the National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, Glaxo-SmithKline, Psyadon and Forest Laboratories pharmaceuticals; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; has consulted for gambling and legal entities on issues related to addictions or impulse control disorders; has provided clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MA GP. Performed the experiments: RJK. Analyzed the data: HY CH SM. Contributed reagents/materials/analysis tools: GP MA. Wrote the paper: HY. Edited manuscript: MP GP MA CH. Advised on analysis: GP MA.